Riona

Ferric Citrate

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Riona

Property	Description
Active ingredient	Ferric Citrate Hydrate
Form	Tablet (Oral preparation)
Pharmacological class	Phosphate Binder / Oral Iron Replacement Product
Common use	Managing high phosphate and low iron levels
Origin	Synthetic (Iron-based compound)

What is Riona? Definition and Active Ingredient

Riona is a prescription-only pharmaceutical preparation delivered as an oral tablet, whose sole active ingredient is Ferric Citrate Hydrate, known by the generic name Ferric Citrate. This medicine is an iron-based compound formulated as a single active ingredient product intended for the oral route of administration. Chemically, Ferric Citrate Hydrate contains ferric iron (Fe³⁺) and citrate, a synthetic structure that differentiates its function from simple iron salts. Ferric Citrate is recognized for its ability to control serum phosphate concentration.

What Type of Drug is Ferric Citrate (Riona)?

Ferric Citrate is classified as a dual-acting agent belonging to two distinct pharmacological classes: it is both a Phosphate Binder and an Oral Iron Replacement Product. This dual functionality is the substance's primary distinguishing feature, setting it apart from non-iron-containing phosphate binders. The agent is used to manage phosphate levels in adults with Chronic Kidney Disease on dialysis. Clinically, this dual mechanism is considered advantageous for patient populations, as it links the management of mineral balance directly with the critical need to address concurrent iron deficiency.

What is the General Purpose of Riona?

The general purpose of Riona is to manage elevated phosphate levels and support the improvement of low iron status in adult patient populations, particularly those with Chronic Kidney Disease (CKD). The medication works by utilizing the ferric iron component to actively bind to dietary phosphate, which helps to decrease the serum phosphate concentration. Simultaneously, the compound provides absorbable iron to the system, helping to replenish iron stores and consequently assisting in the management of Iron Deficiency Anemia (IDA). This comprehensive approach addresses both Hyperphosphatemia and iron deficiency with one preparation.

Regulatory References

What side effects are possible with Riona?

Possible Side Effects and Safety Information

Ferric Citrate (Riona) is associated with an official safety profile categorized by adverse reactions and explicit safety constraints documented by government regulatory agencies.

Frequency-Classified Adverse Reactions

The adverse reactions most frequently reported in controlled clinical studies are predominantly related to the gastrointestinal system. Regulatory documents classify these effects based on frequency:

Classification	Adverse Reaction	Incidence Rate	System-Organ Class
Very Common	Discolored feces, Diarrhea, Constipation, Nausea	ge 10%	Gastrointestinal Disorders
Common	Vomiting, Abdominal pain, Hyperkalemia, Cough	1% to 10%	GI/Metabolism/Respiratory

Other commonly reported reactions include headache, classified under Nervous System Disorders.

Serious Safety Constraints and Limitations

The use of this medication is subject to high-level restrictions documented in official labeling due to the risks associated with the iron content:

Contraindication: Iron Overload Syndromes The medication is contraindicated in individuals with known iron overload syndromes, such as hemochromatosis. This is due to the potential for the iron component to exacerbate the condition.
Accidental Overdose Risk Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age, and this warning is mandated in the official prescribing information.
Drug Absorption Interference Ferric Citrate may bind to and potentially reduce the absorption of certain other oral medications, which is a required consideration in the regulatory safety profile.

Population-Specific Safety Statements

Official regulatory documents address the safety status for specific patient groups:

Pediatric Population: The safety and effectiveness of the medicine have not been established in pediatric patients.
Older Adults (Geriatric): Studies performed to date have not identified age-specific problems that would generally limit the usefulness of this medication in older adults.
Pregnancy and Lactation: There are no adequate and well-controlled safety studies available to establish the drug-associated risk for use in pregnant women or during breastfeeding.

Duration-Related Safety Monitoring

Due to the medicine's ferric iron content, its regulatory safety profile requires the periodic assessment and monitoring of iron storage parameters, such as serum ferritin and transferrin saturation (TSAT), during the course of treatment to assess the risk of excessive iron accumulation.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory prescribing information for Riona (Ferric Citrate Hydrate) notes that no specific clinical data are available regarding acute overdose in patients. The official guidance on overdose risk and emergency actions focuses primarily on the potential for iron-related toxicity and cumulative exposure.

Required Emergency Actions

Due to the inherent risks associated with iron compounds, regulatory authorities mandate that individuals must contact a doctor or poison control center immediately following any suspected or accidental overdose of this medicine. This immediate action is crucial, as accidental ingestion of iron-containing products is officially documented as a leading cause of fatal poisoning, particularly in children under six years of age.

Documented Risks and Monitoring

The risk of chronic or cumulative overdose exists due to the potential for excessive systemic iron absorption. This can lead to iron overload, which is recognized by laboratory findings such as elevated serum ferritin and Transferrin Saturation (TSAT). Consequently, routine monitoring of these levels is required to manage the risk of developing excessive iron stores. Specific population considerations also note that iron overdose in pregnant women may be linked to severe outcomes, including spontaneous abortion and fetal malformation. Management in overdose situations typically involves supportive care.

Therapeutic Uses of Riona

What Riona Treats: Main Uses and Benefits

Riona (Ferric Citrate Hydrate) is generally used to address two relevant, coexisting clinical needs frequently faced by adults with Chronic Kidney Disease (CKD): managing systemic imbalance and improving inadequate iron status. This dual application is considered relevant within comprehensive CKD care.

This medication is applied across domains where additional symptomatic support is needed, specifically for the control of hyperphosphatemia and for the treatment of Iron Deficiency Anemia (IDA) in CKD patients. It is commonly used when groups of symptoms, such as the pronounced fatigue and generalized weakness characteristic of anemia, interfere with daily comfort. This dual therapeutic approach supports patients during symptomatic phases and assists with maintaining functional stability.

“This dual therapeutic approach supports patients during difficult episodes by easing distress related to systemic imbalance.”

Quick Fact: Supportive Management for Systemic Imbalance

Control of Elevated Blood Phosphate Levels

This medication is used to address persistently elevated levels of phosphate in the blood, in conditions where functional stability becomes affected. This therapeutic use provides supportive relief in situations of systemic imbalance, which may assist with easing the symptom burden related to systemic imbalance.

Improvement of Iron Deficiency Anemia

Riona is considered relevant in contexts involving heightened systemic burden due to iron deficiency. It is commonly used to help with the pronounced fatigue and generalized weakness characteristic of IDA. By addressing the root cause of iron deficiency, this therapeutic approach supports patients during symptomatic phases.

Regulatory References

DailyMed (FDA) prescribing information

Eligibility and Restrictions for Use

Official Eligibility Profile: Riona (Ferric Citrate Hydrate)

This section outlines the patient populations eligible for treatment with Riona, based on official regulatory labeling from government health authorities, including those in Japan, the United States, and Europe.

Populations Who Must Not Use the Medicine (Contraindications)

Riona is contraindicated and must not be used by patients with the following conditions:

Iron Overload Syndromes: Patients with documented conditions of excessive iron in the body, such as hemochromatosis.
Hypersensitivity: Patients with a known allergy or severe sensitivity to ferric citrate or any non-active ingredients in the medication.
Severe Hypophosphataemia: Patients with critically low phosphate levels.

Populations Requiring Special Consideration (Restrictions)

Age: Use is not established for the pediatric population (children and adolescents) as sufficient safety and efficacy data are not available.
Pregnancy and Lactation: Use is generally not recommended. There are no adequate studies to confirm safety during pregnancy. Use during breastfeeding requires careful assessment due to the potential for infant iron exposure.
Pre-existing Conditions: Caution is advised, and use may be restricted, for patients with pre-existing conditions like active gastrointestinal bleeding or severe inflammatory bowel disorders.
Iron Status Monitoring: Patients must undergo continuous monitoring of iron parameters (ferritin and TSAT). Treatment may need to be interrupted or discontinued if levels indicate emerging iron overload.

What should I know about interactions with other medicines?

Riona Interactions with other medicines and products

The interaction profile of Riona (Ferric Citrate Hydrate) is defined primarily by its function as an iron-based compound that acts locally in the gastrointestinal tract. Regulatory documents categorize these interactions as pharmacokinetic alterations, mainly involving binding or chelation that reduces the systemic exposure of co-administered medicines.

Documented Interactions and Regulatory Constraints

The co-administration of Riona with several medicines, including fluoroquinolone antibiotics (e.g., Ciprofloxacin) and tetracycline antibiotics (e.g., Doxycycline), can lead to a documented decrease in the level or effect of the antibiotic. To mitigate this effect, official labeling specifies mandatory time separation rules for administration. Similarly, other agents, such as the iron chelator Deferiprone and the agent Vadadustat, also require a minimum time separation when taken with Riona.

An important pharmacodynamic interaction exists with other iron-containing products, specifically Intravenous Iron. Concomitant use with parenteral iron may result in an additive risk of Iron Overload due to excessive elevation in systemic iron stores. Due to this risk, Riona is contraindicated in patients with pre-existing iron overload syndromes, such as Hemochromatosis.

Finally, the absorption of Riona itself can be decreased by co-administration with certain agents, including acid-reducing medicines (H2 blockers, PPIs), and also by certain foods, specifically Dairy Food and Phytic Acid containing foods, a restriction noted in regulatory information.

Mechanism of Action

How Riona Works

Riona's action is defined by a dual mechanistic approach centered on the ferric iron ( Fe^3+) component, simultaneously influencing two distinct physiological systems through separate pathways.

Gastrointestinal Phosphate Sequestration

The compound acts as a binder in the gut lumen, resulting in a mechanism of extracellular sequestration. The ferric iron forms a strong chemical bond with dietary phosphate to create insoluble ferric phosphate. This binding prevents the net absorption of phosphate across the intestinal wall, initiating a cascade that leads directly to a decrease in the systemic serum phosphate concentration.

Systemic Iron Transport and Utilization

A separate action involves the compound providing a source of absorbable iron. Unbound Fe^3+ is reduced and actively transported across the intestinal mucosa via the DMT-1 protein, entering the systemic circulation. Here, it is taken up by Transferrin and delivered to tissues. This mechanism contributes to increasing systemic iron stores (Ferritin) and elevates iron transport capacity, which is a physiological consequence for iron-dependent processes.

Modulation of Mineral Homeostasis

The mechanism of reducing serum phosphate concentration has an indirect downstream effect on key regulatory systems. By modulating the systemic phosphate load, the drug influences the signals that control mineral bone metabolism, such as the levels of Fibroblast Growth Factor 23 (FGF23). This provides a physiological adjustment influencing overall mineral balance pathways.

Dosage and Administration Information

How Riona is Used

The usage of Riona (Ferric Citrate Hydrate) involves a specific administration route, dosing schedules, and consumption requirements. This medication is exclusively for oral administration as a 1 gram film-coated tablet.

Dosing and Administration Schedule

Ferric Citrate is taken three times per day (TID) and must be consumed with meals. This timing is essential for the medication to perform its function as a phosphate binder. The tablets are intended to be swallowed whole and must not be chewed or crushed. The maximum recommended dose for adults is 12 tablets daily.

Clinical Application	Standard Adult Starting Dose	Titration Method
Hyperphosphatemia (CKD on Dialysis)	2 tablets TID (6 tablets/day)	Adjusted at intervals of one week or more based on serum phosphorus
Iron Deficiency Anemia (CKD Not on Dialysis)	1 tablet TID (3 tablets/day)	Adjusted at intervals of one week or more based on hemoglobin and iron status

Dose Adjustment and Specific Populations

The dose is not fixed and must be titrated (adjusted) in small increments or decrements (1 to 2 tablets per day) at intervals of one week or more, with the goal of maintaining target laboratory levels. For older adults (65 years and older), no specific dosage adjustment is required. However, for the pediatric population (18 years and younger), the safety and efficacy of Riona have not been established, and dosing instructions are not available.

Recent Clinical Evidence

Riona: Recent Clinical Evidence

Clinical research involving ferric citrate hydrate (Riona) primarily focuses on its investigational use in hyperphosphatemia associated with chronic kidney disease (CKD) and in iron deficiency anemia (IDA).

Investigational Use in Chronic Kidney Disease (CKD)

Studies have explored the compound's use as an oral phosphate binder in adult patients with CKD, including those who are both on dialysis and not on dialysis. Phase 3 studies evaluated whether the compound was associated with changes in serum phosphorus concentration in patients with hyperphosphatemia. Research findings characterizing the safety and tolerability profile were explored in long-term administration studies.

Research in Iron Deficiency Anemia (IDA)

The compound has also been the subject of research in adult patients with IDA. A pivotal Phase 3 randomized, double-blind study examined Riona in comparison to a control drug (sodium ferrous citrate) over a seven-week period. The primary endpoint assessed whether Riona was non-inferior to the control drug in the change in hemoglobin level from baseline.

Key research findings related to comparison groups:

Focus Area	Research Finding (Investigational)
Efficacy comparison	Non-inferiority to the control drug was observed in the change in hemoglobin levels.
Gastrointestinal Tolerability	Lower incidence rates of nausea and vomiting were observed with Riona compared to the control drug in the comparative Phase 3 study.

Tolerability Profile

Reported adverse events from clinical trials generally relate to gastrointestinal measures. These studies primarily serve to characterize the compound’s profile, including the influence of food intake on compound absorption and tolerability measures.

Frequently Asked Questions (FAQ)

Common questions about Riona (FAQ)

Q: Can Riona cause long-term side effects that I should know about?

Official regulatory documents caution that the iron component in Riona can lead to excessive elevations in the body's iron stores over time. This risk is why continuous monitoring of blood iron parameters, such as ferritin and TSAT, is required during treatment. If monitoring indicates elevated iron levels, a healthcare provider may need to interrupt or modify the treatment.

Q: What happens if I accidentally miss a dose of Riona?

If a dose is missed, official regulatory guidance often suggests taking it as soon as the patient remembers. However, if it is close to the time for the next scheduled dose, the missed dose should be skipped. Regulatory information cautions against taking a double dose to compensate for a missed dose.

Q: Can Riona affect my ability to drive or operate machinery?

Official product information lists common side effects, such as headache, that could potentially affect concentration or motor skills. Patients who experience side effects like weakness or confusion should consult official warnings and exercise caution regarding driving or operating machinery. Official guidance emphasizes the need for patients to be aware of how the medicine affects their personal condition.

Q: Why do some people say Riona didn't work for them?

Official documents indicate the need for dose adjustment to maintain target phosphorus and iron levels, suggesting individual patient response may vary. Additionally, gastrointestinal adverse reactions were the most common reason patients discontinued the product in clinical studies, which is another documented factor that may limit continued use.

Q: How long can someone safely take Riona for a chronic condition?

The official documentation does not specify a maximum time limit for using the medication. However, due to the potential for excessive iron accumulation, long-term administration is associated with the requirement for continuous, periodic monitoring of iron parameters, which may lead to treatment interruption.

Q: Does Riona come in different strengths or formulations?

According to the official prescribing information, Riona is supplied as a 1 gram film-coated tablet for oral use. This 1-gram tablet is the only strength and formulation available.

Q: Does Riona affect fertility?

Official product information states that the medicine has not been studied for effects on human fertility. Nonclinical data from animal studies have shown potential for adverse effects on offspring development when high doses of related iron compounds were administered.

Q: Is Riona habit-forming or addictive?

Official regulatory agencies, such as the FDA, have not classified Riona as a controlled substance. This means it is not considered to be habit-forming or to have a potential for abuse.

Q: Can Riona be safely stopped suddenly, or does it need to be tapered?

Official information advises against stopping the medication suddenly. Any decision regarding discontinuation or tapering of the treatment should be made only by a healthcare provider.

How should Riona be stored and disposed of?

How to Store and Dispose of Riona?

The storage of Riona (Ferric Citrate Hydrate) must comply with Controlled Room Temperature requirements, maintaining the tablets between 20°C to 25°C (68 F to 77 F). The medication must be protected from moisture, requiring the container to be kept tightly closed.

Once the bottle is first opened, the contents must be used within 60 days.

Child-Safety and Disposal

It is mandatory to keep this iron-containing product out of the reach of children due to the risk of accidental overdose and subsequent fatal poisoning. Unused or expired Riona should be discarded using a formal drug take-back program. If one is unavailable, tablets should be mixed with an unappealing substance, placed in a sealed bag, and disposed of in household trash; tablets must not be crushed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Japan

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z